Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2008-03-17
2009-10-27
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C530S317000, C514S009100
Reexamination Certificate
active
07608280
ABSTRACT:
Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.
REFERENCES:
patent: 4977138 (1990-12-01), Okuhara et al.
patent: 6403555 (2002-06-01), Skov
patent: 6548479 (2003-04-01), Skov
patent: 7056884 (2006-06-01), Nakajima et al.
patent: 0 352 646 (1990-01-01), None
patent: 4-79892 (1992-03-01), None
patent: WO 01/42282 (2001-06-01), None
Hirotsugu Ueda, et al., “FR901228, A Novel Antitumor Bicyclic Depsipeptide Produced byChromobacterium violaceumNo. 968”, I. “Taxonomy, Fermentation, Isolation, Physico-Chemical and Biological Properties, and Antitumor Activity”, The Journal of Antibiotics (1994), vol. 47, No. 3, pp. 301-310.
Sshigematsu, et al., “FR901228, A Novel Antitumor Bicyclic Depsipeptide Produced bychromobacterium violaceumNo. 968”, II. “Structure Determination”, The Journal of Antibiotics (1994), vol. 47, No. 3, pp. 311-314.
Khan W. Li et al, “Total Synthesis of the Antitumor Depsipeptide FR-901,228”, J. Am. Chem. Soc., 1996, 118, pp. 7237-7238.
Material Safety Data Sheet: (E-(1S, 4S, 10S, 21R)-7-[(Z)-ethylidene]4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraaza-3,6,9,19-pentaoxobibyclo[8,7,6]-tricos-16-ene (1993).
Higaki Tomoji
Kanda Munekazu
Matsuda Mitsunori
Tsuboi Masaru
Ueda Satoshi
Astellas Pharma Inc.
Kosar Andrew D
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Method of producing FR901228 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of producing FR901228, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of producing FR901228 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079187